{"pmid":32363911,"title":"Telepsychiatry as a public health imperative: Slowing COVID-19.","text":["Telepsychiatry as a public health imperative: Slowing COVID-19.","Aust N Z J Psychiatry","Khanna, Rahul","Forbes, Malcom","32363911"],"journal":"Aust N Z J Psychiatry","authors":["Khanna, Rahul","Forbes, Malcom"],"date":"2020-05-05T11:00:00Z","year":2020,"_id":"32363911","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1177/0004867420924480","topics":["Prevention"],"weight":1,"_version_":1666138495993774080,"score":9.490897,"similar":[{"pmid":32193550,"pmcid":"PMC7184488","title":"Public health measures to slow community spread of COVID-19.","text":["Public health measures to slow community spread of COVID-19.","J Infect Dis","Cowling, Benjamin J","Aiello, Allison","32193550"],"journal":"J Infect Dis","authors":["Cowling, Benjamin J","Aiello, Allison"],"date":"2020-03-21T11:00:00Z","year":2020,"_id":"32193550","source":"PubMed","week":"202012|Mar 16 - Mar 22","doi":"10.1093/infdis/jiaa123","topics":["Prevention"],"weight":1,"_version_":1666138490052542464,"score":57.784363},{"pmid":32434596,"title":"The Use of Telepsychiatry During COVID-19 and Beyond.","text":["The Use of Telepsychiatry During COVID-19 and Beyond.","The COVID-19 pandemic has disrupted the traditional practice of psychiatric assessment and treatment via face to face interaction. Telepsychiatry, the delivery of psychiatric care remotely through telecommunications technology, is an existing and under-utilised tool that may help to minimise disruption to patient care. Technological advancement is at a stage where it can facilitate widespread use of this practice; however concerns that limited its expansion previously were not unfounded. This article discusses the use of telepsychiatry in the context of the COVID-19 pandemic.","Ir J Psychol Med","O'Brien, M","McNicholas, F","32434596"],"abstract":["The COVID-19 pandemic has disrupted the traditional practice of psychiatric assessment and treatment via face to face interaction. Telepsychiatry, the delivery of psychiatric care remotely through telecommunications technology, is an existing and under-utilised tool that may help to minimise disruption to patient care. Technological advancement is at a stage where it can facilitate widespread use of this practice; however concerns that limited its expansion previously were not unfounded. This article discusses the use of telepsychiatry in the context of the COVID-19 pandemic."],"journal":"Ir J Psychol Med","authors":["O'Brien, M","McNicholas, F"],"date":"2020-05-22T11:00:00Z","year":2020,"_id":"32434596","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1017/ipm.2020.54","keywords":["covid-19","coronavirus","mental health","pandemic","psychiatry","technology","telemedicine","telepsychiatry"],"weight":0,"_version_":1667521393680449538,"score":48.544712},{"pmid":32475309,"title":"Considerations for Telepsychiatry Service Implementation in the Era of COVID-19.","text":["Considerations for Telepsychiatry Service Implementation in the Era of COVID-19.","Psychiatr Serv","Jordan, Ayana","Dixon, Lisa B","32475309"],"journal":"Psychiatr Serv","authors":["Jordan, Ayana","Dixon, Lisa B"],"date":"2020-06-02T11:00:00Z","year":2020,"_id":"32475309","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1176/appi.ps.71605","topics":["Prevention"],"weight":1,"_version_":1668437835012636672,"score":43.555393},{"pmid":32238358,"title":"Clinical Research Slows as COVID-19 Surges.","text":["Clinical Research Slows as COVID-19 Surges.","As the COVID-19 pandemic worsens, the clinical cancer community is grappling with how to continue providing access to experimental but potentially lifesaving therapies while keeping immunocompromised patients safe. To that end, cancer centers are making changes to their clinical trial programs, while pharmaceutical companies are deciding how-or whether-trials should continue.","Cancer Discov","32238358"],"abstract":["As the COVID-19 pandemic worsens, the clinical cancer community is grappling with how to continue providing access to experimental but potentially lifesaving therapies while keeping immunocompromised patients safe. To that end, cancer centers are making changes to their clinical trial programs, while pharmaceutical companies are deciding how-or whether-trials should continue."],"journal":"Cancer Discov","date":"2020-04-03T11:00:00Z","year":2020,"_id":"32238358","source":"PubMed","week":"202014|Mar 30 - Apr 05","doi":"10.1158/2159-8290.CD-NB2020-021","topics":["General Info"],"weight":1,"_version_":1666138490410106880,"score":40.83494}]}